A new Perspective article in the New England Journal of Medicine examines a recent decision by a Philadelphia judge to reject the argument that an overdose prevention site, called Safehouse, would violate the Controlled Substances Act.

The decision signals a move toward an approach to regulating drugs that minimizes both the harms of drugs and the harms caused by regulation itself – worthy goals all around, the authors write.